Ortho Dermatologics, one of the largest prescription dermatology health care businesses in the world and a division of Bausch Health...
Quidel Corporation and Ortho Clinical Diagnostics Holdings plc announced that they have entered into a definitive agreement in which Quidel will acquire Ortho, one of the world’s largest in vitro diagnostics companies, for $24.68 per share of common stock using a combination of cash and newly issued shares in the combined company, representing a 25% premium over Ortho’s closing price on December 22, 2021 and an equity value of approximately $6.0 billion.
Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. announced that the FDA has accepted the New Drug Application (NDA)...
Bausch Health Companies Inc.and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced that...
Ortho Dermatologics has resubmitted an application to market its plaque psoriasis lotion Duobrii in the US. The move follows receipt...
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its...
Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced...
Ortho Dermatologics has submitted a New Drug Application (NDA) to the U.S. FDA for IDP 118 (halobetasol propionate and tazarotene)...
Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. announced that it has received a Complete Response Letter (CRL) from...